| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF00389899 |
| P953 | full work available at URL | http://link.springer.com/content/pdf/10.1007/BF00389899.pdf |
| http://link.springer.com/article/10.1007/BF00389899/fulltext.html | ||
| http://link.springer.com/content/pdf/10.1007/BF00389899 | ||
| P698 | PubMed publication ID | 410178 |
| P2093 | author name string | R. Gönnert | |
| P. Andrews | |||
| P2860 | cites work | Jean-Baptiste François Pierre Bulliard | Q1246173 |
| Studies with the schistosomicide oxamniquine (UK-4271) I. Activity in rodents and in vitro | Q34052869 | ||
| Influence of parasite strain on chemotherapy of murine infections with Schistosoma mansoni | Q36720555 | ||
| Protection against human schistosome cercariae | Q39969136 | ||
| Experimental chemotherapy of schistosomiasis mansoni. XIII. Activity of praziquantel, an isoquinoline-pyrazino derivative, on mice, hamsters and Cebus monkeys | Q41323055 | ||
| The susceptibility to praziquantel of Schistosoma haematobium in the baboon (Papio anubis) and of S. japonicum in the vervet monkey (Cercopithecus aethiops) | Q41323073 | ||
| The structure-activity relationship in several schistosomicidal compounds | Q41883060 | ||
| Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. | Q43706400 | ||
| The efficacy of praziquantel against cestodes in cats, dogs and sheep | Q44388870 | ||
| Susceptibility of Schistosoma mansoni from Liberia and Puerto Rico to antischistosomal drugs | Q46720616 | ||
| The efficacy of praziquantel against cestodes in animals | Q50968447 | ||
| Experimental chemoprophylaxis against schistosomiasis. I. Introduction and rationale. | Q52733401 | ||
| An Improved Perfusion Technique for Recovering Adult Schistosomes from Laboratory Animals | Q53755844 | ||
| A new active metabolite of "Miracil D". | Q53790645 | ||
| The relative chemotherapeutic efficacy of a nitrovinylfuran (SQ 18,506) against immature and mature stages of Schistosoma mansoni. | Q54046816 | ||
| A comparison of the susceptibility to praziquantel of Schistosoma haematobium, S. japonicum, S. mansoni, S. intercalatum and S. mattheei im hamsters | Q67682007 | ||
| [Effect of hycanthone at different evolutive stages of experimental infection of the mouse by Schistosoma mansoni] | Q68543672 | ||
| Experimental chemoprophylaxis against schistosomiasis. II. Stage I comparison of lucanthone, hycanthone, niridazole and oxamniquine (UK 4271) | Q69675861 | ||
| Schistosoma mansoni: Early antimonial treatment of infected mice | Q69750160 | ||
| The control of immatureSchistosoma mansoniin mice by UK 3883, a novel 2-aminomethyltetrahydroquinoline derivative | Q70561571 | ||
| Comparative studies of the action of mirasan, lucanthone, hycanthone and niridazole againstSchistosoma mansoniin mice | Q71838835 | ||
| Comparison of biological effects by programmed probit analysis | Q72859007 | ||
| [Dependence on host and parasite strain of the successful therapy of experimental schistosomiasis] | Q73810786 | ||
| Efficacy of a 2-Phenyl Quinoline against Experimental Schistosoma mansoni Infections in Mice and Monkeys | Q76460473 | ||
| CHEMOTHERAPY OF EXPERIMENTAL SCHISTOSOMIASIS MANSONI: PROPHYLACTIC AND PROTECTIVE ACTIVITY OF CLINICALLY ACTIVE COMPOUNDS IN MICE AND HAMSTERS | Q76675059 | ||
| CHEMOTHERAPY OF EXPERIMENTAL SCHISTOSOMIASIS MANSONI: PROPHYLACTIC, PROTECTIVE AND THERAPEUTIC ACTIVITY OF SODIUM ANTIMONY DIMERCAPTOSUCCINATE AND ANTIMONY DIMERCAPTOSUCCINIC ACID IN MICE AND HAMSTERS | Q76966917 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | praziquantel | Q424145 |
| P304 | page(s) | 129-150 | |
| P577 | publication date | 1977-07-01 | |
| 1977-07-21 | |||
| P1433 | published in | Zeitschrift für Parasitenkunde (Berlin, Germany) | Q27713931 |
| P1476 | title | Praziquantel, a new board-spectrum antischistosomal agent | |
| Praziquantel, a new broad-spectrum antischistosomal agent | |||
| P478 | volume | 52 |
| Q44983935 | A benzodiazepine derivative and praziquantel: effects on musculature of Schistosoma mansoni and Schistosoma japonicum |
| Q35801990 | A blood fluke serine protease inhibitor regulates an endogenous larval elastase |
| Q67682007 | A comparison of the susceptibility to praziquantel of Schistosoma haematobium, S. japonicum, S. mansoni, S. intercalatum and S. mattheei im hamsters |
| Q64243898 | A novel cell-free method to culture Schistosoma mansoni from cercariae to juvenile worm stages for in vitro drug testing |
| Q64947379 | A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection. |
| Q69038524 | Absorption, distribution and excretion of the anthelmintic praziquantel (Droncit) in rainbow trout (Salmo gairdneri R.). |
| Q34230702 | Activity of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine against Schistosomiasis mansoni in mice |
| Q39225562 | Adverse effects of praziquantel treatment of Schistosoma japonicum infection: involvement of host anaphylactic reactions induced by parasite antigen release |
| Q39392929 | An international initiative on praziquantel use. |
| Q28545088 | Anthelmintic activity in vivo of epiisopiloturine against juvenile and adult worms of Schistosoma mansoni |
| Q35663977 | Anti-Schistosomal Activity of Cinnamic Acid Esters: Eugenyl and Thymyl Cinnamate Induce Cytoplasmic Vacuoles and Death in Schistosomula of Schistosoma mansoni |
| Q42239154 | Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis |
| Q38975059 | Anti-schistosome chemotherapy enhanced by antibodies specific for a parasite esterase. |
| Q36394751 | Antioxidant and hepatoprotective role of gold nanoparticles against murine hepatic schistosomiasis |
| Q37674908 | Antischistosomal activity of a calcium channel antagonist on schistosomula and adult Schistosoma mansoni worms |
| Q37450784 | Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro. |
| Q38077463 | Application of praziquantel in schistosomiasis japonica control strategies in China |
| Q60949181 | Artemether and Praziquantel: Origin, Mode of Action, Impact, and Suggested Application for Effective Control of Human Schistosomiasis |
| Q24615049 | Bioactivity of miltefosine against aquatic stages of Schistosoma mansoni, Schistosoma haematobium and their snail hosts, supported by scanning electron microscopy |
| Q83769924 | Bioavailability and in vivo efficacy of a praziquantel-polyvinylpyrrolidone solid dispersion in Schistosoma mansoni-infected mice |
| Q37557828 | Chapter 4. Peptidases of trematodes |
| Q28539314 | Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis |
| Q57157512 | Chemotherapy for Fighting Schistosomiasis: Past, Present and Future |
| Q35841575 | Chemotherapy for major food-borne trematodes: a review |
| Q68732251 | Chemotherapy of experimental Echinococcus multilocularis in jirds |
| Q39729825 | Chemotherapy of parasitic infections |
| Q79239916 | Chemotherapy of schistosomiasis: an update |
| Q28328165 | Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics |
| Q35536096 | Clinical study evaluating efficacy of praziquantel in clonorchiasis |
| Q34939414 | Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials |
| Q46237917 | Comparative Analysis of Proteome-Wide Lysine Acetylation in Juvenile and Adult Schistosoma japonicum |
| Q37771992 | Controlling schistosomiasis in Southeast Asia: a tale of two countries |
| Q37726920 | Controlling schistosomiasis with praziquantel: How much longer without a viable alternative? |
| Q37405246 | Current chemotherapy arsenal for schistosomiasis mansoni: alternatives and challenges |
| Q36877133 | Current status of medicinal research in helminth diseases |
| Q40547961 | Cytokine patterns in experimental schistosomiasis mansoni infected mice treated with silymarin |
| Q33747366 | Design and synthesis of molecular probes for the determination of the target of the anthelmintic drug praziquantel |
| Q44211698 | Detection of circulating anodic antigen before and after specific chemotherapy in experimental murine schistosomiasis mansoni |
| Q28543164 | Development and validation of a luminescence-based, medium-throughput assay for drug screening in Schistosoma mansoni |
| Q39300204 | Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content Screening |
| Q27306843 | Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening |
| Q99719959 | Drug metabolism and pharmacokinetics of praziquantel: A review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models |
| Q53605480 | Effect of adamantylamide dipeptide as adjuvant therapy to praziquantel in mice infected with different S. mansoni isolates. |
| Q35773009 | Effect of an integrated control strategy for schistosomiasis japonica in the lower reaches of the Yangtze River, China: an evaluation from 2005 to 2008 |
| Q39544935 | Effect of combined treatment with praziquantel and artemether on Schistosoma japonicum and Schistosoma mansoni in experimentally infected animals |
| Q41763237 | Effect of praziquantel on certain immune responses of schistosomal Egyptian patients. I. Changes of specific immunoglobulins |
| Q46797403 | Effect of praziquantel on some aspects of carbohydrate metabolism in mice infected with Schistosoma mansoni |
| Q33884547 | Effect of praziquantel on the differential expression of mouse hepatic genes and parasite ATP binding cassette transporter gene family members during Schistosoma mansoni infection |
| Q44441883 | Effect of praziquantel on the distribution of interstitial collagen types I and III and basement membrane collagen types IV and V in murine hepatic schistosomiasis |
| Q67400835 | Effect of praziquantel on the free living stages of Schistosoma mansoni |
| Q44093477 | Effect of praziquantel prolonged administration on granuloma formation around Schistosoma japonicum eggs in lung of sensitized mice |
| Q73576307 | Effect of praziquantel together with artemether on Schistosoma japonicum parasites of different ages in rabbits |
| Q69091747 | Effect of praziquantel treatment on lung-stage larvae of Schistosoma mansoni in vivo |
| Q51400781 | Effect of the in vivo activity of dihydroartemisinin against Schistosoma mansoni infection in mice. |
| Q70790142 | Effects of free and liposomized praziquantel on worm burden and antibody response in mice infected with Mesocestoides corti tetrathyridia |
| Q69709333 | Effects of praziquantel on human intestinal flukes (Fasciolopsis buski and Heterophyes heterophyes) |
| Q38452685 | Efficacy and side-effects of two praziquantel treatments against Schistosoma haematobium infection, among schoolchildren from Côte d'Ivoire |
| Q37544555 | Evaluation of the anti-Schistosoma mansoni activity of thiosemicarbazones and thiazoles |
| Q44641141 | Evaluation of the safety of ivermectin-praziquantel administered orally to pregnant mares |
| Q35960717 | Evolutionary concepts in predicting and evaluating the impact of mass chemotherapy schistosomiasis control programmes on parasites and their hosts |
| Q49171947 | Experimental chemotherapy of Schistosoma curassoni in mice |
| Q67984511 | Experimental chemotherapy of Schistosoma mansoni with praziquantel and oxamniquine: differential effect of single or combined formulations of drugs on various strains and on both sexes of the parasite |
| Q41323055 | Experimental chemotherapy of schistosomiasis mansoni. XIII. Activity of praziquantel, an isoquinoline-pyrazino derivative, on mice, hamsters and Cebus monkeys |
| Q37373792 | Expression, immunolocalization and serodiagnostic value of a myophilin-like protein from Schistosoma japonicum. |
| Q71187170 | Factors affecting the acquisition of resistance against Schistosoma mansoni in the mouse. V. Reduction in the degree of resistance to reinfection after chemotherapeutic elimination of recently patent primary infections |
| Q69002001 | Fasciola hepatica: tegumental surface alterations following treatment in vitro with the deacetylated (amine) metabolite of diamphenethide |
| Q33642023 | Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles |
| Q47988412 | Further studies on mefloquine and praziquantel alone or interaction of both drugs against Schistosoma japonicum in vitro |
| Q39786591 | Genetic activities of hycanthone and some other antischistosomal drugs |
| Q28552824 | Global Assessment of Schistosomiasis Control Over the Past Century Shows Targeting the Snail Intermediate Host Works Best |
| Q37280789 | Imaging schistosomes in vivo |
| Q39257435 | Immune dependence of schistosomicidal chemotherapy: an ultrastructural study of Schistosoma mansoni adult worms exposed to praziquantel and immune serum in vivo |
| Q35224451 | Immune-dependent chemotherapy of schistosomiasis |
| Q42859585 | Immunological and parasitological parameters after treatment with dexamethasone in murine Schistosoma mansoni |
| Q37292213 | In Vitro Schistosomicidal Activity of Phytol and Tegumental Alterations Induced in Juvenile and Adult Stages of Schistosoma haematobium |
| Q28542999 | In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoni |
| Q64068974 | In vitro and in vivo activities of DW-3-15, a commercial praziquantel derivative, against Schistosoma japonicum |
| Q27339703 | In vitro and in vivo anti-schistosomal activity of the alkylphospholipid analog edelfosine |
| Q43713527 | In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel |
| Q96816954 | Investigating the antifibrotic effect of the antiparasitic drug Praziquantel in in vitro and in vivo preclinical models |
| Q51741191 | Investigations on the interplays between Schistosoma mansoni, praziquantel and the gut microbiome. |
| Q51191319 | Is there a reduced sensitivity of dihydroartemisinin against praziquantel-resistant Schistosoma japonicum? |
| Q42920406 | Is there reduced susceptibility to praziquantel in Schistosoma japonicum? Evidence from China |
| Q52506843 | Light and electron microscopic studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro. |
| Q48578173 | London School of Hygiene and Tropical Medicine Meeting at Keppel Street, London, 12 April 2000. The Professor Gerald Webbe Memorial Lecture: global control of schistosomiasis |
| Q89967832 | MicroRNA-21 Mediates the Inhibiting Effect of Praziquantel on NLRP3 Inflammasome in Schistosoma japonicum Infection |
| Q36990847 | Microarray based analysis of temperature and oxidative stress induced messenger RNA in Schistosoma mansoni |
| Q38807251 | Modern approaches to accelerate discovery of new antischistosomal drugs. |
| Q39211542 | Morphological effects and tegumental alterations induced by mefloquine on schistosomula and adult flukes of Schistosoma mansoni |
| Q36675102 | Multicentre trials of praziquantel in human schistosomiasis: design and techniques |
| Q44042514 | Mutagenicity studies with Praziquantel, a new anthelmintic drug, in mammalian systems |
| Q40817009 | Mutagenicity studies with praziquantel, a new anthelmintic drug: Tissue-, host-, and urine-mediated mutagenicity assays |
| Q38334179 | Natural products as leads in schistosome drug discovery. |
| Q37177725 | New approaches for understanding mechanisms of drug resistance in schistosomes |
| Q37943763 | New insight into praziquantel against various developmental stages of schistosomes |
| Q34163477 | New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni |
| Q39386825 | Parasitological evaluation of Ro 15-9268, a 9-acridanone-hydrazone derivative against Schistosoma mansoni in mice, and observations on changes in serum enzyme levels |
| Q46921243 | Pharmacodynamics of mefloquine and praziquantel combination therapy in mice harbouring juvenile and adult Schistosoma mansoni |
| Q51034558 | Pharmacokinetics of new high-concentration and long-acting praziquantel oily suspensions after intramuscular administration in cattle. |
| Q35281233 | Polymorphism associated with the Schistosoma mansoni tetraspanin-2 gene |
| Q36099895 | Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy. |
| Q52206275 | Population dynamics of Schistosoma mansoni in mice repeatedly exposed to infection. |
| Q44574643 | Potential antifibrotic effects of AT1 receptor antagonist, losartan, and/or praziquantel on acute and chronic experimental liver fibrosis induced by Schistosoma mansoni |
| Q70419881 | Praziquantel |
| Q48622699 | Praziquantel Targets M1 Macrophages and Ameliorates Splenomegaly in Chronic Schistosomiasis |
| Q80983687 | Praziquantel and the benzodiazepine Ro 11-3128 do not compete for the same binding sites in schistosomes |
| Q36441487 | Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance |
| Q73338045 | Praziquantel has no direct effect on (Na(+)+K+)-ATPases and (Ca2(+)-Mg2+)ATPases of Schistosoma mansoni |
| Q35607817 | Praziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine Schistosoma mansoni infection |
| Q28484303 | Praziquantel synergistically enhances paclitaxel efficacy to inhibit cancer cell growth |
| Q46797056 | Praziquantel treatment of Biomphalaria glabrata infected with Schistosoma mansoni--influence on snail fecundity |
| Q67879080 | Praziquantel treatment of muscle Taenia solium cysticercosis. 4. Reversible in vitro effect |
| Q45065380 | Praziquantel-induced exposure of Schistosoma mansoni alkaline phosphatase: drug-antibody synergy which acts preferentially against female worms |
| Q24677485 | Praziquantel: a new schistosomicide against Schistosoma haematobium |
| Q28475935 | Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni |
| Q44026136 | Reduction in the prevalence and intensity of hookworm infections after praziquantel treatment for schistosomiasis infection |
| Q43778585 | Reinfection with Schistosoma haematobium following school-based chemotherapy with praziquantel in four highly endemic villages in Côte d'Ivoire |
| Q39544940 | Relative contribution of day-to-day and intra-specimen variation in faecal egg counts of Schistosoma mansoni before and after treatment with praziquantel |
| Q34125799 | Research and development of antischistosomal drugs in the People's Republic of China a 60-year review |
| Q33735929 | Revisiting glucose uptake and metabolism in schistosomes: new molecular insights for improved schistosomiasis therapies |
| Q36664391 | Scanning and transmission electron microscope studies on the efficacy of praziquantel on Hymenolepis nana (Cestoda) in vitro |
| Q46793864 | Schistosoma japonicum-infected hamsters (Mesocricetus auratus) used as a model in experimental chemotherapy with praziquantel, artemether, and OZ compounds |
| Q41527168 | Schistosoma mansoni: Activity responses in vitro to praziquantel |
| Q44093854 | Schistosoma mansoni: Angiotensin converting enzyme activity in mice under the influence of praziquantel and/or captopril |
| Q40147049 | Schistosoma mansoni: The effects of a subcurative dose of praziquantel on the ultrastructure of worms in vivo |
| Q71088008 | Schistosoma mansoni: dose-related tegumental surface changes after in vivo treatment with praziquantel |
| Q54350844 | Schistosoma mansoni: enhanced efficacy of praziquantel treatment in immune mice. |
| Q52242503 | Schistosoma mansoni: stage-dependent damage after in vivo treatment with praziquantel. |
| Q39381400 | Schistosomes: challenges in compound screening |
| Q34573786 | Schistosomiasis Drug Therapy and Treatment Considerations |
| Q36459174 | Schistosomiasis--a century searching for chemotherapeutic drugs. |
| Q34998245 | Schistosomiasis--a rich vein of research |
| Q38984212 | Schistosomicidal and molluscicidal activities of aminoalkylamino substituted neo- and norneocryptolepine derivatives |
| Q44567644 | Sequence and level of endogenous expression of calcium channel beta subunits in Schistosoma mansoni displaying different susceptibilities to praziquantel |
| Q35927520 | Sexual biology of schistosomes |
| Q41875321 | Significant intrapulmonary Schistosoma egg antigens are not present in schistosomiasis-associated pulmonary hypertension |
| Q54448067 | Stability of Schistosoma mansoni progeny to antischistosomal drugs. |
| Q33687475 | Structural insights into a 20.8-kDa tegumental-allergen-like (TAL) protein from Clonorchis sinensis |
| Q37409571 | Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis |
| Q70399501 | Studies on chemotherapy of parasitic helminths (IX). Effects of praziquantel on the motility of various parasitic helminths and isolated host tissues |
| Q35593046 | Suppression of the Insulin Receptors in Adult Schistosoma japonicum Impacts on Parasite Growth and Development: Further Evidence of Vaccine Potential |
| Q38050973 | Susceptibility or resistance of praziquantel in human schistosomiasis: a review |
| Q33504927 | Susceptibility to praziquantel of male and female cercariae of praziquantel-resistant and susceptible isolates of Schistosoma mansoni |
| Q39607879 | Synthesis of fluorescent derivatives of praziquantel: cell-imaging and interaction with Schistosoma japonicum cercariae |
| Q60053808 | TPT sulfonate, a single, oral dose schistosomicidal prodrug: In vivo efficacy, disposition and metabolic profiling |
| Q43762877 | Tegumental alterations in juvenile Schistosoma haematobium harboured in hamsters following artemether treatment |
| Q37071406 | Telmisartan, an AT1 receptor blocker and a PPAR gamma activator, alleviates liver fibrosis induced experimentally by Schistosoma mansoni infection |
| Q28552173 | The Schistosomiasis Clinical Trials Landscape: A Systematic Review of Antischistosomal Treatment Efficacy Studies and a Case for Sharing Individual Participant-Level Data (IPD) |
| Q58070149 | The anti-schistosomal drug praziquantel is an adenosine antagonist |
| Q56514272 | The antidepressant drug paroxetine as a new lead candidate in schistosome drug discovery |
| Q43823575 | The effect of Nigella sativa oil against the liver damage induced by Schistosoma mansoni infection in mice |
| Q41688910 | The effect of Praziquantel on Schistosoma mansoni |
| Q42472011 | The effect of praziquantel on the ultrastructure of Schistosoma margrebowiei. |
| Q50968447 | The efficacy of praziquantel against cestodes in animals |
| Q44388870 | The efficacy of praziquantel against cestodes in cats, dogs and sheep |
| Q41395086 | The efficacy of praziquantel against experimental cysticercosis and hydatidosis (author's transl) |
| Q34455017 | The potential of artemether for the control of schistosomiasis |
| Q36850831 | The schistosome in the mammalian host: understanding the mechanisms of adaptation |
| Q35910564 | The sensitivity of Schistosoma japonicum to praziquantel: a field evaluation in areas with low endemicity of China |
| Q41323073 | The susceptibility to praziquantel of Schistosoma haematobium in the baboon (Papio anubis) and of S. japonicum in the vervet monkey (Cercopithecus aethiops) |
| Q33914691 | Towards an understanding of the mechanism of action of praziquantel |
| Q46470767 | Tranilast ameliorates impaired hepatic functions in Schistosoma mansoni-infected mice |
| Q36442593 | Transcriptional analysis of Schistosoma mansoni treated with praziquantel in vitro |
| Q43832848 | Transmission electron microscopic observations on ultrastructural damage in juvenile Schistosoma mansoni caused by artemether |
| Q53691679 | Treatment of fish parasites. 1. Praziquantel effective against Monogenea (Dactylogyrus vastator, Dactylogyrus extensus, Diplozoon paradoxum). |
| Q70871918 | Treatment of human fascioliasis with niclofolan |
| Q46497362 | Ultrastructural changes of adult Schistosoma mansoni worms recovered from C57BL/6 mice passively immunized with normal and vaccinated rabbit sera in vivo |
| Q70746971 | Ultrastructural investigations on the effect of praziquantel on the tegument of five species of cestodes |
| Q38264085 | Vaccines and diagnostics for zoonotic schistosomiasis japonica. |
| Q36579608 | Wharton's jelly-derived mesenchymal stem cells combined with praziquantel as a potential therapy for Schistosoma mansoni-induced liver fibrosis |
| Q71248355 | [New aspects in the field of parasitology and parasitic diseases of man] |
Search more.